Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
BELLINGS Intelligence Score: 10
Why it matters
This is routine corporate news about investor sentiment toward Novo Nordisk's outlook, with no immediate or broad credit-market impact.
Sources
The New York Times Business
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.